|
1
|
Yang J, Chen S, Yang Y, Ma X, Shao B, Yang
S, Wei Y and Wei X: Jumonji domain-containing protein 6 protein and
its role in cancer. Cell Prolif. 53:e127472020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Poulard C, Rambaud J, Lavergne E,
Jacquemetton J, Renoir JM, Tredan O, Chabaud S, Treilleux I, Corbo
L and Le Romancer M: Role of JMJD6 in breast tumourigenesis. PLoS
One. 10:e01261812015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee YF, Miller LD, Chan XB, Black MA, Pang
B, Ong CW, Salto-Tellez M, Liu ET and Desai KV: JMJD6 is a driver
of cellular proliferation and motility and a marker of poor
prognosis in breast cancer. Breast Cancer Res. 14:R852012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu X, Si W, Liu X, He L, Ren J, Yang Z,
Yang J, Li W, Liu S, Pei F, et al: JMJD6 promotes melanoma
carcinogenesis through regulation of the alternative splicing of
PAK1, a key MAPK signaling component. Mol Cancer. 16:1752017.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lee CR, Lee SH, Rigas NK, Kim RH, Kang MK,
Park NH and Shin KH: Elevated expression of JMJD6 is associated
with oral carcinogenesis and maintains cancer stemness properties.
Carcinogenesis. 37:119–128. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang J, Ni SS, Zhao WL, Dong XC and Wang
JL: High expression of JMJD6 predicts unfavorable survival in lung
adenocarcinoma. Tumour Biol. 34:2397–2401. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wan J, Liu H, Yang L, Ma L, Liu J and Ming
L: JMJD6 promotes hepatocellular carcinoma carcinogenesis by
targeting CDK4. Int J Cancer. 144:2489–2500. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zheng H, Tie Y, Fang Z, Wu X, Yi T, Huang
S, Liang X, Qian Y, Wang Xi, Pi R, et al: Jumonji domain-containing
6 (JMJD6) identified as a potential therapeutic target in ovarian
cancer. Signal Transduct Target Ther. 4:242019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang F, He L, Huangyang P, Liang J, Si W,
Yan R, Han X, Liu S, Gui B, Li W, et al: JMJD6 promotes colon
carcinogenesis through negative regulation of p53 by hydroxylation.
PLoS Biol. 12:e10018192014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miller TE, Liau BB, Wallace LC, Morton AR,
Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, et al:
Transcription elongation factors represent in vivo cancer
dependencies in glioblastoma. Nature. 547:355–359. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou DX, Zhou D, Zhan SQ, Wang P, Qin K,
Gan W and Lin XF: Inhibition of JMJD6 expression reduces the
proliferation, migration and invasion of neuroglioma stem cells.
Neoplasma. 64:700–708. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aprelikova O, Chen K, El Touny LH,
Brignatz-Guittard C, Han J, Qiu T, Yang HH, Lee MP, Zhu M and Green
JE: The epigenetic modifier JMJD6 is amplified in mammary tumors
and cooperates with c-Myc to enhance cellular transformation, tumor
progression, and metastasis. Clin Epigenetics. 8:382016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zaneker P, Gray ES and Ziman MR:
Autoantibody production in cancer-the humoral immune response
toword autologous antigens in cancer patients. Autoimmun Rev.
15:477–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ushigome M, Shimada H, Miura Y, Yoshida K,
Kaneko T, Koda T, Nagashima Y, Suzuki T, Kagami S and Funahashi K:
Changing pattern of tumor markers in recurrent colorectal cancer
patients before surgery to recurrence: Serum p53 antibodies, CA19-9
and CEA. Int J Clin Oncol. 25:622–632. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sumazaki M, Shimada H, Ito M, Shiratori F,
Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Iwadate Y, Mine S,
et al: Serum anti-LRPAP1 is a common biomarker for digestive organ
cancers and atherosclerotic diseases. Cancer Sci. 111:4453–4464.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hiwasa T, Wang H, Goto K, Mine S, Machida
T, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Sata M, et al:
Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as
predictive risk markers for acute ischemic stroke. BMC Med.
19:1312021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li SY, Yoshida Y, Kobayashi E, Kubota M,
Matsutani T, Mine S, Machida T, Maezawa Y, Takemoto M, Yokote K, et
al: Serum anti-AP3D1 antibodies are risk factors for acute ischemic
stroke related with atherosclerosis. Sci Rep. 11:134502021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kanda Y: Investigation of the freely
available easy-to-use software ‘EZR’ for medical statistics. Bone
Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maes T, Carceller E, Salas J, Ortega A and
Buesa C: Advances in the development of histone lysine demethylase
inhibitors. Curr Opin Pharmacol. 23:52–60. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ran T, Xiao R, Huang Q, Yuan H, Lu T and
Liu W: In silico discovery of JMJD6 inhibitors for cancer
treatment. ACS Med Chem Lett. 10:1609–1613. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ushigome M, Shimada H, Nabeya Y, Shiratori
F, Soda H, Takiguchi N, Hoshino I, Kuwajima A, Kaneko T and
Funahashi K: Possible predictive significance of serum RalA
autoantibodies on relapse-free survival in patients with colorectal
cancer. Mol Clin Oncol. 14:182021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ushigome M, Nabeya Y, Soda H, Takiguchi N,
Kuwajima A, Tagawa M, Matsushita K, Koike J, Funahashi K and
Shimada H: Multi-panel assay of serum autoantibodies in colorectal
cancer. Int J Clin Oncol. 23:917–923. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takashi S, Satoshi Y, Akihiko O, Naoya Y,
Yusuke T, Kentaro M, Yu O, Yasuaki N, Koichi Y, Takashi F, et al:
Clinical impact of preoperative serum p53 antibody titers in 1487
patients with surgically treated esophageal squamous cell
carcinoma: A multi-institutional study. Esophagus. 18:65–71. 2021.
View Article : Google Scholar : PubMed/NCBI
|
